Shots:

• The P-III ENSEMBLE trial involves assessing COVID-19 vaccine vs PBO in 43-783 enrolled participants aged ≥18yrs. with both mod. and sev. COVID-19 disease
• The trial met all 1EP & 2EPs i.e 85% efficacy in preventing disease- vaccine efficacy was consistent against symptomatic infection including in South Africa and Brazil that showed a high prevalence of SARS-CoV-2 variants
• Additionally- the trial met its co-1EPs of protecting against mod. to sev. COVID-19 that showed 67% efficacy @14days and 66 % efficacy @28days after vaccination. The vaccine demonstrated efficacy as early as 7days after vaccination- with efficacy continuing to increase 8wks. post-vaccination

  Ref: J&J | Image: Market Watch